The Hook
The GLP-1 revolution just entered a new chapter. In January 2026, the FDA approved oral semaglutide (Wegovy in pill form) for weight management—the first GLP-1 receptor agonist available as a pill for weight loss. And on the horizon, with an FDA decision expected by April 10, 2026, is orforglipron, Eli Lilly's next-generation oral GLP-1 that could reshape the entire landscape of medically assisted weight management.
For athletes, bodybuilders, and active adults who have been watching the injectable GLP-1 phenomenon from the sidelines, concerned about needles, muscle loss, or the commitment of weekly injections, this is a pivotal moment. The question is no longer whether GLP-1 therapy works, but how to use it intelligently within an active lifestyle.
The Science: How Oral GLP-1 Agents Work
GLP-1 (glucagon-like peptide-1) receptor agonists mimic a natural gut hormone that regulates appetite, insulin secretion, and gastric emptying. The result: reduced hunger, improved blood sugar control, and significant weight loss. The OASIS 4 trial demonstrated 13.6% mean body weight loss at 64 weeks with oral semaglutide 25 mg—comparable to injectable formulations.
Orforglipron represents a true leap forward. Unlike semaglutide, which is a modified peptide requiring special absorption-enhancing formulations, orforglipron is a small-molecule, non-peptide compound, meaning it's more stable, easier to manufacture, and potentially more affordable. Phase 3 data showed weight loss of 7.5% to 11.2% at 72 weeks depending on dose, with head-to-head data showing orforglipron 36 mg producing 73.6% greater weight loss than oral semaglutide 14 mg.
A major concern for athletes has been muscle loss during GLP-1 therapy. Recent data from the ATTAIN-MAINTAIN trial showed that patients transitioning to orforglipron after injectable GLP-1 therapy maintained their weight loss with minimal regain (approximately 0.9 kg after semaglutide transition), suggesting that oral maintenance strategies could minimize the lean mass depletion seen with prolonged high-dose injectable therapy.
Beyond weight loss, the expanding therapeutic landscape of GLP-1 agonists now includes cardiovascular risk reduction, peripheral artery disease management, and active clinical trials for neurodegenerative disorders and substance use disorders—with over 15 global trials underway for the latter indication alone.
The Solution at P.O.W.
At Prisk Orthopaedics & Wellness, medically assisted weight management is never a one-size-fits-all prescription. Dr. Prisk integrates GLP-1 therapy within a comprehensive metabolic optimization framework that includes body composition monitoring via ultrasound scanning, personalized resistance training programs to preserve lean mass, nutritional counseling calibrated to training demands, and hormone optimization (TRT/HRT) when clinically indicated.
For athletes and active patients, the arrival of oral GLP-1 options opens new possibilities. Imagine managing body composition with a daily pill, supported by structured training and metabolic monitoring, no injections, no disruption to your routine. Combined with peptide therapy and targeted supplementation, P.O.W. offers a fully integrated approach to performance-oriented weight management.
If you've been considering GLP-1 therapy but held off due to the injectable format, or if you're already on therapy and want expert guidance on protecting muscle mass and performance, P.O.W. is your partner.
Ready to Take the Next Step?
Schedule your consultation with Dr. Prisk today at orthoandwellness.com or call our office directly. Whether you're a competitive athlete or a weekend warrior, P.O.W. delivers elite-level care tailored to your goals.
